Journavx is a non‑opioid oral painkiller approved for adults with moderate‑to‑severe acute pain. It blocks sodium‑channel pain signals in the body, relieving pain without addiction risk.
Approval Date
30-Jan-25
NCE-1 Date
30-Jan-29
NCE Date
30-Jan-30
Commercial snapshot
Market performance & projections
Revenue ($M)
60
CAGR (%)
113.56%
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
507
2027
590
2028
911
2029
1,248
2030
1,592
2031
1,930
2032
2,277
Molecule profile
Details & specifications
Molecule
Suzetrigine
Innovator
VERTEX PHARMACEUTICALS INC
Dosage Form
Oral Tablet
Strength
50 mg
Therapeutic Category
Analgesic
Usage
To treat moderate to severe acute pain
Good to know
Frequently asked questions
Ready to act on this opportunity?
Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.